Last reviewed · How we verify
Herpes labialis
Approved treatments
- Abreva · University of Utah
- Abreva
- Aciclovir · Assistance Publique Hopitaux De Marseille
- Zovirax · Ligand Pharms
Acyclovir works by mimicking a building block of DNA to prevent the herpes virus from replicating. - Denavir · Mylan
Denavir works by inhibiting the DNA polymerase enzyme of the herpes virus, preventing it from replicating and causing infection. - Valtrex · GSK
Valtrex works by inhibiting the replication of herpes simplex virus DNA through interference with viral DNA polymerase. - ACYC · Ligand Pharms
Acyc works by binding to a specific target in the body, although its exact mechanism is unknown.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Herpes labialis patent landscape — cliff calendar, originator estates, attackable patents
- Herpes labialis treatment landscape brief
- Herpes labialis treatment updates RSS
Frequently asked questions about Herpes labialis
What drugs treat Herpes labialis?
Tracked treatments include Abreva, Aciclovir, Zovirax, Denavir, Valtrex, ACYC.
What is the treatment for Herpes labialis?
Standard treatment for Herpes labialis includes Abreva, Aciclovir, Zovirax, Denavir, Valtrex. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Herpes labialis patent cliff · Herpes labialis CI report
- Treatment: Abreva · University of Utah
- Treatment: Abreva
- Treatment: Aciclovir · Assistance Publique Hopitaux De Marseille
- Treatment: Zovirax · Ligand Pharms
- Treatment: Denavir · Mylan
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing